All the Active Ingredient Drugs
Aldosterone Antagonist. Eplerenone 25 mg, 50 mg. F.C. TABS.:28. For the individ. adjust. of dose, of 25 mg, 50 mg are available. The max. dose 50 mg dly.
For post-MI heart fail. pts.: The recomm. maint. dose of eplerenone is 50 mg×1/d. Tmt. should be initiated at 25 mg×1/d and titrat. to the target dose of 50 mg×1/d preferably within 4 wks., taking into account the serum K+ level. Eplerenone ther. should usually be start. within 3-14 d after an acute MI. See lit.
For pts. with NYHA class II (chron.) heart fail.: For chron. heart fail. NYHA class II pts., tmt. should be init. at a dose of 25 mg×1/d and titrat. to the target dose of 50 mg×1/d preferably within 4 wks.; taking into account the serum K+ level. See lit.
Eplerenone is indicated: In addit. to standard ther. include. β-block., to reduce the risk of CV mortal. & morbid. in stable pts. with left LVEF ≤ 40 % and clin. evidence of heart fail. after recent MI.
In addit. to standard optimal ther., to reduce the risk of CV mortal. and morbid. in adult pts. with NYHA class II (chron.) heart fail. and left ventric. syst. dysfunct. (LVEF ≤30%).
C/I: Hypersens. Pts. with serum K+ level > 5.0 mmol/L at init. Pts. with sev. renal insuffic. (eGFR <30 mL per min. per 1.73 m²). Pts. with sev. hep. insuffic. (Child-Pugh Class C). Pts. receiv. K+-spar. diuretics, strong inhib. of CYP 3A4 (e.g., itraconazole, ketoconazole, ritonavir, nelfinavir, clarithromycin, telithromycin, nefazodone). The comb. of an ACE's inhib. and an ARB's inhib with eplerenone.